Diffuse Large B Cell Lymphoma
269
57
89
70
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
21 trials with published results (8%)
Research Maturity
70 completed trials (26% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.4%
20 terminated out of 269 trials
77.8%
-8.8% vs benchmark
7%
19 trials in Phase 3/4
30%
21 of 70 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 70 completed trials
Clinical Trials (269)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Split-Dose R-CHOP for Older Adults With DLBCL
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia